ການບໍາບັດເເຊນສ່ວນປະສົມຈຸລັງ
「ການບໍາບັດເເຊນສ່ວນປະສົມຈຸລັງ」对应一条老挝专利公开记录，由 KOLON TISSUEGENE, INC 于 2020-03-30 提交申请，当前状态为等待形式审查。公开档案中可核验：申请号 P/800，DIP 编号 LAP800，主管局代码 LA，保护类型 Patent - PCT National Phase。时间线要点：公开/公告日 2026-01-23。国际分类 / IPC 标注为 A61K 35/32。发明人 / 设计人包括 LEE, Kwan, Hee、NOH, Moon, Jong、SONG, Sun, Uk、Yl, Youngsuk。代理机构 / 代理人记载为 CONCETTI- Representative Bureau in LAOS.。公开摘要提示：The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first popul…。
This Laos patent “MIXED-CELL GENE THERAPY” is a public DIP intellectual-property record, filed by KOLON TISSUEGENE, INC on 2020-03-30; current status: Awaiting formal examination. Identifiers include application No. P/800; DIP id LAP800; protection kind Patent - PCT National Phase. Key dates: publication 2026-01-23. Classification: A61K 35/32. Inventor(s)/designer(s): LEE, Kwan, Hee, NOH, Moon, Jong, SONG, Sun, Uk, Yl, Youngsuk. Abstract hint: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first popul…. Unique application identifiers, holders and classification text are surfaced here to reduce near-duplicate IP landing pages; always verify against the competent office.
ໜ້ານີ້ສະຫຼຸບ ສິດທິບັດ «ການບໍາບັດເເຊນສ່ວນປະສົມຈຸລັງ» ຈາກຂໍ້ມູນຈົດທະບຽນເປີດ, ຍື່ນໂດຍ KOLON TISSUEGENE, INC ໃນວັນທີ 2020-03-30; ສະຖານະ ລໍຖ້າກວດຮູບແບບ. ຕົວລະບຸ: ເລກທີຄຳຮ້ອງ P/800; ລະຫັດ DIP LAP800; ປະເພດການປົກປ້ອງ Patent - PCT National Phase. ວັນທີສຳຄັນ: ວັນເຜີຍແຜ່ 2026-01-23. ປະເພດ/ຫ້ອງ: A61K 35/32. ນັກປະດິດ/ນັກອອກແບບ: LEE, Kwan, Hee, NOH, Moon, Jong, SONG, Sun, Uk, Yl, Youngsuk. ສະຫຼຸບ: The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first popul…. ຂໍ້ມູນເພື່ອອ້າງອີງເທົ່ານັ້ນ ບໍ່ແມ່ນຄຳແນະນຳທາງກົດໝາຍ ຫຼື ໃບຢັ້ງຢືນສິດ.
P/800
图样
基础信息
- 类型
- 专利
- 申请号
P/800- 状态
- 等待形式审查
- 申请人
- KOLON TISSUEGENE, INC
- 代理机构
- CONCETTI- Representative Bureau in LAOS.
- 申请日期
- 2020-03-30
- 公开/公告日
- 2026-01-23
- 国际分类
- A61K 35/32
- 商品 / 服务
- —
办理流程
根据当前状态动态标注-
提交申请
-
形式审查 进行中
-
实质审查
-
公开
-
授权
关联分析
LaoBiz 企业数据库联动类似专利推荐
摘要
The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.
The subject invention is directed to a mixed cell composition to generate a therapeutic protein at a target site by providing a first population of mammalian cells transfected or transduced with a gene that is sought to be expressed, and a second population of mammalian cells that have not been transfected or transduced with the gene, wherein endogenously existing forms of the second population of mammalian cells are decreased at the target site, and wherein generation of the therapeutic protein by the first population of mammalian cells at the target site stimulates the second population cells to induce a therapeutic effect.